Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Returns Astellas’s JAK Inhibitor

This article was originally published in PharmAsia News

Executive Summary

A ‘strategic portfolio decision’ is behind the return by Johnson & Johnson company Janssen Biotech of broad rights to Astellas’ oral Janus Kinase (JAK) inhibitor, ASP015K, effective 15 Jan.

You may also be interested in...



Publisher's Spotlight: Clinical And Research Excellence Honored At The Citeline Awards

Informa Pharma Intelligence congratulates the winners of the fifth annual awards. 

Publisher's Spotlight: Clinical And Research Excellence Honored At The Citeline Awards

Informa Pharma Intelligence congratulates the winners of the fifth annual awards. 

Ultragenyx Enters Duchenne Gene Therapy Space In $295m Deal With Solid Biosciences

Ultragenyx enters a competitive and complicated market, but the combination of its manufacturing platform with Solid’s transgene could provide an advantage. 

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel